Titan Medical Inc.
TMDIF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $500 | $444 |
| % Growth | – | -100% | 12.5% | – |
| Cost of Goods Sold | $0 | $0 | $89 | $33 |
| Gross Profit | $0 | $0 | $411 | $412 |
| % Margin | – | – | 82.1% | 92.7% |
| R&D Expenses | $0 | -$103 | -$592 | $88 |
| G&A Expenses | $1,104 | $943 | $642 | $1,136 |
| SG&A Expenses | $1,104 | $939 | $570 | $1,089 |
| Sales & Mktg Exp. | -$0 | -$4 | -$72 | -$47 |
| Other Operating Expenses | $8 | $0 | -$44 | -$436 |
| Operating Expenses | $1,104 | $836 | -$66 | $740 |
| Operating Income | -$1,104 | -$836 | -$24 | -$329 |
| % Margin | – | – | -4.7% | -74% |
| Other Income/Exp. Net | $42 | $33 | -$3,284 | $843 |
| Pre-Tax Income | -$1,062 | -$803 | -$3,308 | $67 |
| Tax Expense | $3 | $0 | $25 | $0 |
| Net Income | -$1,065 | -$803 | -$3,333 | $68 |
| % Margin | – | – | -666.5% | 15.3% |
| EPS | -0.009 | -0.007 | -0.029 | 0.001 |
| % Growth | -32.9% | 76% | -4,966.7% | – |
| EPS Diluted | -0.009 | -0.007 | -0.029 | 0.001 |
| Weighted Avg Shares Out | 114,040 | 114,040 | 114,040 | 113,213 |
| Weighted Avg Shares Out Dil | 114,040 | 114,040 | 114,040 | 129,108 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $100 | $108 | $172 |
| Interest Expense | $32 | $35 | $38 | $41 |
| Depreciation & Amortization | $0 | $0 | $89 | $33 |
| EBITDA | -$1,030 | -$769 | -$3,094 | $140 |
| % Margin | – | – | -618.8% | 31.6% |